Treatment-resistant depression affects a substantial subset of patients diagnosed with major depressive disorder, representing a population for whom sequential antidepressant trials have consistently failed to produce remission (Rush et al., 2006). The approval of SPRAVATO® (esketamine) nasal spray by the U.S. Food and Drug Administration marked one of the most significant developments in depression pharmacology in decades, offering a mechanism of action fundamentally different from conventional monoamine-based antidepressants. At Complete Mind Care in Villanova, we are proud to be among the certified treatment centers in the greater Philadelphia region providing SPRAVATO® treatment within a closely monitored, clinically rigorous setting designed to optimize outcomes for patients who have not found relief through conventional approaches.
What Makes Treatment-Resistant Depression Different
Major depressive disorder (MDD) is a profoundly disabling condition, but treatment-resistant depression (TRD) represents a distinct and more severe clinical challenge. By established clinical criteria, TRD is commonly defined as an inadequate response to at least two antidepressant medications of adequate dose and duration (Gaynes et al., 2020). For many patients in Villanova and across the Delaware County Main Line communities, this definition describes years — sometimes decades — of cycling through SSRIs, SNRIs, tricyclics, augmentation strategies, and combination regimens, each with diminishing returns and accumulating side effect burden.
The neurobiological underpinnings of TRD are increasingly understood to involve glutamatergic dysfunction, synaptic plasticity deficits, and neuroinflammatory dysregulation that monoamine-targeting agents cannot fully address (Duman et al., 2019). This is precisely the gap that SPRAVATO® was designed to fill. By acting as an N-methyl-D-aspartate (NMDA) receptor antagonist, esketamine rapidly modulates glutamate transmission and promotes downstream pathways involved in synaptic plasticity in prefrontal and limbic regions — a mechanism associated with antidepressant effects that may emerge faster than the weeks often required by conventional antidepressants. For a deeper look at the clinical landscape of patients who have exhausted standard options, our overview of treatment-resistant depression breakthrough options beyond medication provides helpful context.
FDA Approval and Clinical Indications
SPRAVATO® is FDA-approved for two distinct indications: treatment-resistant depression in adults, as monotherapy or in conjunction with an oral antidepressant, and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant (Janssen Pharmaceuticals, 2025). These approvals reflect the clinical evidence base and define the patient populations for whom SPRAVATO® represents an appropriate and evidence-supported intervention.
It is important to note these approvals precisely — SPRAVATO® is not approved for all forms of depression, and its use outside these indications would be considered off-label. At Complete Mind Care, we conduct a thorough medication history review and work with each patient to determine whether SPRAVATO® is appropriate as part of their individualized treatment plan, including whether an oral antidepressant should be continued, adjusted, or initiated based on the specific indication and clinical profile.
How SPRAVATO® Treatment Works at Our Villanova Clinic
Because SPRAVATO® carries a Risk Evaluation and Mitigation Strategy (REMS) program due to risks including sedation, dissociation, respiratory depression, abuse and misuse, and increased blood pressure, all treatment must occur in a certified healthcare setting (Janssen Pharmaceuticals, 2025). At our Villanova clinic at 795 E Lancaster Ave, Suite 210, patients self-administer the nasal spray under direct clinical supervision, then remain in our monitored setting for a minimum of two hours post-dose. This observation period allows our clinical team to assess adverse effects, provide support if dissociative symptoms occur, and ensure patients are safe to leave before discharge.
The standard induction phase for TRD involves two sessions per week for four weeks, followed by a maintenance phase that typically transitions to weekly then weekly or every-two-week dosing based on clinical response and tolerability (Janssen Pharmaceuticals, 2025). Throughout this process, our team monitors symptom response using validated rating scales, adjusts the treatment schedule as clinically indicated, and coordinates with any concurrent psychotherapy providers to support the broader therapeutic benefit of care. Results vary by individual, and we communicate realistic expectations clearly from the outset.
Who May Be Appropriate for SPRAVATO®
Candidates for SPRAVATO® at our Villanova clinic generally include patients who have experienced two or more adequate antidepressant trials without sufficient response, those with a documented history of treatment-resistant depression, or individuals currently experiencing depressive symptoms in a major depressive episode with acute suicidal ideation or behavior. We also evaluate patients who have had partial responses to prior treatments and whose residual symptom burden continues to impair daily functioning.
Discuss with your provider whether SPRAVATO® is appropriate for your specific situation. Certain contraindications exist, including aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage, or known hypersensitivity to esketamine, ketamine, or any excipients in the formulation (Janssen Pharmaceuticals, 2025). Our initial consultation process involves a comprehensive medical and psychiatric history to identify any contraindications and to ensure treatment safety.
Barriers to Access and How We Help
Among the most significant barriers we encounter for patients across the Main Line and Delaware County who are appropriate candidates for SPRAVATO® is the complexity of insurance prior authorization. Because SPRAVATO® is a higher-cost specialty medication administered in a monitored setting, payers typically require extensive documentation of prior treatment failures, current diagnosis, and clinical necessity. Our clinical team has experience navigating these requirements and assists patients in compiling the necessary clinical history to support authorization requests efficiently.
A second barrier involves the practical logistics of a treatment that requires two monitored hours in our clinic. Many patients in Villanova’s professional community initially express concern about time commitment given work and family responsibilities. We work with patients to identify scheduling solutions that accommodate their lives, including early morning and flexible scheduling options designed to minimize disruption to work and family obligations. We believe that access to evidence-based brain-based therapies cannot be contingent on a patient’s ability to navigate administrative or scheduling obstacles alone.
Integrating SPRAVATO® Within a Comprehensive Treatment Plan
SPRAVATO® is most effective when integrated within a broader treatment architecture. At Complete Mind Care, we view each patient’s course of care as a dynamic and individualized plan that may combine SPRAVATO® with concurrent psychotherapy, medication management, TMS, or other interventions based on clinical presentation and goals. Research increasingly supports the concept of a post-treatment neuroplasticity window — a period during which synaptic remodeling may be heightened and the brain may be particularly responsive to therapeutic input (Abdallah et al., 2018). Where clinically appropriate, we coordinate psychotherapy sessions to leverage this window and support longer-term outcomes.
Remission is our mission. For patients in Villanova and across the greater Philadelphia region who have been told that their depression is simply “treatment resistant” with no further options, we offer a different perspective: treatment-resistant means that the right treatment has not yet been found, and our clinical team is committed to finding it.
FAQ
What is SPRAVATO® and how is it different from ketamine infusions?
SPRAVATO® (esketamine) is an FDA-approved nasal spray that acts on NMDA glutamate receptors to produce antidepressant effects. Unlike IV ketamine infusions — which are administered as racemic ketamine and are not FDA-approved specifically for depression — SPRAVATO® is esketamine, the S-enantiomer of ketamine, and is FDA-approved for treatment-resistant depression and depressive symptoms in adults with MDD with acute suicidal ideation or behavior. SPRAVATO® is administered in a certified clinical setting and is covered by insurance for appropriate candidates, whereas IV ketamine is typically considered off-label.
How quickly does SPRAVATO® work?
Some patients report meaningful symptom improvement within hours to days of their first few SPRAVATO® sessions, which distinguishes it from conventional antidepressants that often require several weeks for initial response. This rapid onset can be particularly significant for patients experiencing acute suicidal ideation or severe functional impairment. Full stabilization and sustained response typically develop over the four-week induction phase and into the maintenance period. Results vary by individual.
Is SPRAVATO® covered by insurance?
SPRAVATO® is covered by many major insurance plans for patients who meet the FDA-approved indications, including treatment-resistant depression. Coverage typically requires prior authorization and documentation of prior treatment failures. Our clinical and administrative team works with patients to navigate this process and to submit the documentation required for approval.
Will I be able to drive myself home after SPRAVATO® treatment?
No. Due to the potential for sedation and dissociative effects in the two-hour post-dose observation period, patients are not permitted to drive on the day of SPRAVATO® administration. We require that patients arrange for a responsible adult to accompany them or arrange transportation. We discuss transportation logistics with every patient during the initial consultation to ensure this is planned in advance.
Can SPRAVATO® be used alongside my current antidepressant?
Yes. SPRAVATO® is FDA-approved for treatment-resistant depression as monotherapy or in conjunction with an oral antidepressant, and it is FDA-approved for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant (Janssen Pharmaceuticals, 2025). Our team will review your current medication regimen to determine the optimal approach for your individual clinical situation.
Key Takeaways
- SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression and for depressive symptoms in adults with MDD with acute suicidal ideation or behavior — it is distinct from off-label IV ketamine infusions.
- SPRAVATO® acts on NMDA glutamate receptors, offering a mechanism of action fundamentally different from conventional monoamine-based antidepressants.
- Treatment requires administration in a certified clinical setting with a two-hour monitored observation period; patients cannot drive on treatment days.
- SPRAVATO® may be used as monotherapy or with an oral antidepressant for TRD, while its indication for depressive symptoms in MDD with acute suicidal ideation or behavior requires use with an oral antidepressant.
- Complete Mind Care in Villanova navigates prior authorization, scheduling, and clinical integration to reduce barriers to access for Main Line patients.
Medical Disclaimer: The information provided in this blog is for educational purposes only and does not constitute medical advice. Treatment outcomes vary by individual. Results may vary. Please consult with a qualified healthcare provider before beginning any new treatment. Discuss with your provider whether this treatment is appropriate for you.
Conclusion
For patients on the Main Line and throughout Delaware County who have lived with treatment-resistant depression for months or years, SPRAVATO® represents a scientifically grounded, FDA-approved option with a mechanism of action unlike conventional antidepressants. At Complete Mind Care, our Villanova clinic provides SPRAVATO® treatment within a comprehensive, closely supervised clinical framework developed by professionals who have treated more than 4,500 patients across our practice. If you are ready to explore whether SPRAVATO® may be part of your path to remission, we invite you to schedule a consultation at 795 E Lancaster Ave, Suite 210, Villanova, PA 19085, or call 215-918-7939. Your history with treatment-resistant depression does not define your future — remission is our mission.
References
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018). The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacology & Therapeutics, 190, 148–158. https://doi.org/10.1016/j.pharmthera.2018.05.010
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019). Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron, 102(1), 75–90. https://doi.org/10.1016/j.neuron.2019.03.013
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman-Hoffman, V., Green, J., Hamer, M., Thieda, P., Lloyd, S. W., Lohr, K. N., & Gonsalves, S. (2020). Defining treatment-resistant depression. Depression and Anxiety, 37(2), 134–145. https://doi.org/10.1002/da.22968
Janik, A., Karanikas, C. A., Smith, J. A., Zhang, Y., Lane, R., Hough, D., Daly, E. J., & Singh, J. B. (2025). Esketamine monotherapy in adults with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2025.1183
Janssen Pharmaceuticals. (2025). SPRAVATO® (esketamine) nasal spray, CIII: Prescribing information. https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905